Payment overview · 2025
General Payments
$15,225.73
350 reported records · 46 companies
Healthcare provider profile · identity verified
Anthony A Emmer, D.O.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SOUTHFIELD, MI · NPI 1003819897
Verified facts
What the public records show
CMS Open Payments records show Anthony A Emmer, D.O. received $15,225.73 in general payments during 2025 across 350 reported records.
PFIZER INC. accounted for 54.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 67 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Nurtec Odt, Panzyga, Qulipta, Rexulti, Ubrelvy, Vumerity, Zeposia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rytary by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PLEGRIDY as an associated drug or biological on 39 records involving 31 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Plegridy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vumerity by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zeposia by this doctor in 2024.
HOSPIRA, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 743 records involving 408 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Panzyga by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Octapharma USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 1567 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Panzyga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Panzyga by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $8,289.62 | 54.4% | 19 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $759.11 | 5.0% | 24 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $515.34 | 3.4% | 27 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $445.79 | 2.9% | 36 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $408.70 | 2.7% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $386.21 | 2.5% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $359.29 | 2.4% | 23 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $257.36 | 1.7% | 11 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $254.26 | 1.7% | 14 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $253.92 | 1.7% | 8 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $229.86 | 1.5% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $226.83 | 1.5% | 15 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $181.86 | 1.2% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $180.78 | 1.2% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $179.62 | 1.2% | 8 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $175.84 | 1.1% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $170.15 | 1.1% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $158.28 | 1.0% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.40 | 1.0% | 9 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$119.45 | 0.8% | 6 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.56 | 0.7% | 4 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $97.92 | 0.6% | 5 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $97.52 | 0.6% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $85.65 | 0.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.05 | 0.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $82.85 | 0.5% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $78.19 | 0.5% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$78.14 | 0.5% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $77.65 | 0.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.00 | 0.5% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $67.93 | 0.5% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $64.25 | 0.4% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $63.45 | 0.4% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $62.05 | 0.4% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.30 | 0.4% | 5 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $54.28 | 0.4% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $53.16 | 0.3% | 3 | 2025 |
| HOSPIRA, INC. | Unresolved — no canonical attribution shown | $37.12 | 0.2% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.81 | 0.2% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $31.74 | 0.2% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $30.42 | 0.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.10 | 0.2% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $23.55 | 0.1% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $22.82 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.90 | 0.1% | 1 | 2025 |
| Neuronetics, Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,345.23 | 346 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,300.00 | 2 |
| Consulting Fee | $1,525.00 | 1 |
| Education | $55.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $8,279.00 | 18 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $445.79 | 36 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $408.70 | 12 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $324.13 | 15 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $253.92 | 8 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $232.60 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $226.55 | 14 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $206.07 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $196.37 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $195.56 | 13 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $179.62 | 8 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $175.84 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $170.15 | 7 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $161.31 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $159.27 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $158.28 | 10 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $152.27 | 6 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $150.40 | 9 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $128.25 | 8 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $128.08 | 5 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $126.01 | 6 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $119.45 | 6 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $115.82 | 7 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $108.56 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $102.34 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $97.52 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $96.59 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $85.05 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $83.72 | 6 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $83.20 | 5 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $82.26 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $78.19 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $77.65 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $75.17 | 9 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $69.88 | 6 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $68.55 | 3 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $64.40 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $64.25 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $63.45 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $62.26 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $62.08 | 4 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $62.05 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $62.05 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $60.04 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | HOSPIRA, INC., Octapharma USA, Inc. | $59.94 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $57.30 | 5 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $54.28 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $53.33 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $53.16 | 3 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $51.29 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | HOSPIRA, INC. | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $31.81 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $31.74 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $30.42 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $28.51 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $27.57 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Ormalvi Normalized: ormalvi |
Drug | Cycle Pharmaceuticals Inc | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| NEUROSTAR TMS THERAPY SYSTEM Normalized: neurostar tms therapy system |
Device | Neuronetics, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 52 | exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 94 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | PLEGRIDY open payments reported associated product |
CMS Open Payments — General Payments 39 supporting records · 31 recipient NPIs · example record 1208305761 |
Plegridy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| HOSPIRA, INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 743 supporting records · 408 recipient NPIs · example record 1228796101 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Octapharma USA, Inc. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 1567 supporting records · 974 recipient NPIs · example record 1245074635 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 568 | 166 |
| Pregabalin | Pregabalin | 441 | 142 |
| Memantine Hcl | Memantine Hcl | 420 | 107 |
| Gabapentin | Gabapentin | 356 | 104 |
| Escitalopram Oxalate | Escitalopram Oxalate | 282 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 279 | 72 |
| Clonazepam | Clonazepam | 264 | 46 |
| Baclofen | Baclofen | 235 | 71 |
| Topiramate | Topiramate | 225 | 53 |
| Levetiracetam | Levetiracetam | 218 | 56 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 216 | 61 |
| Primidone | Primidone | 180 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 125 | 34 |
| Lamotrigine | Lamotrigine | 119 | 31 |
| Sumatriptan Succinate | Sumatriptan Succinate | 108 | 19 |
| Rivastigmine | Rivastigmine | 105 | 32 |
| Galantamine Er | Galantamine Hbr | 97 | 26 |
| Lacosamide | Lacosamide | 96 | 27 |
| Ubrelvy | Ubrogepant | 94 | 27 |
| Memantine Hcl Er | Memantine Hcl | 85 | 18 |
| Nortriptyline Hcl | Nortriptyline Hcl | 77 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 21 |
| Trazodone Hcl | Trazodone Hcl | 67 | 23 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 65 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 63 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 57 | 15 |
| Carbamazepine | Carbamazepine | 55 | 18 |
| Emgality Pen | Galcanezumab-Gnlm | 54 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 52 | 12 |
| Mirtazapine | Mirtazapine | 51 | 22 |
| Aimovig Autoinjector | Erenumab-Aooe | 50 | suppressed |
| Alprazolam | Alprazolam | 50 | 15 |
| Methocarbamol | Methocarbamol | 50 | 24 |
| Tramadol Hcl | Tramadol Hcl | 47 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Diazepam | Diazepam | 40 | 26 |
| Teriflunomide | Teriflunomide | 40 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Qulipta | Atogepant | 35 | suppressed |
| Kesimpta Pen | Ofatumumab | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Methylprednisolone | Methylprednisolone | 32 | 27 |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Zonisamide | Zonisamide | 31 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 30 | suppressed |
| Lamotrigine Er | Lamotrigine | 29 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 29 | suppressed |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Prednisone | Prednisone | 28 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 26 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Levetiracetam Er | Levetiracetam | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Gocovri | Amantadine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 18 | suppressed |
| Briviact | Brivaracetam | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Vumerity | Diroximel Fumarate | 18 | suppressed |
| Entacapone | Entacapone | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Dalfampridine Er | Dalfampridine | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Rytary | Carbidopa/Levodopa | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Copaxone | Glatiramer Acetate | 14 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 14 | suppressed |
| Plegridy | Peginterferon Beta-1a | 14 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Carbatrol | Carbamazepine | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Keppra Xr | Levetiracetam | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
| Trileptal | Oxcarbazepine | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,225.73 · 350 records | PFIZER INC. | ACTHAR, AJOVY, AMPYRA, AMVUTTRA, AUSTEDO XR, AVONEX, Auvelity, BOTOX, BREKIYA, BRIUMVI, Bafiertam, Briviact, CREXONT, EPIDIOLEX, FIRDAPSE, FYCOMPA, Fintepla, HYQVIA, Hizentra, INBRIJA, INFINITY, INGREZZA, KESIMPTA, KEVEYIS, KISUNLA, LUMRYZ, Leqembi, Mavenclad, Motpoly XR, NEUROSTAR TMS THERAPY SYSTEM, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus, Ocrevus Zunovo, Ormalvi, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Radicava, Rystiggo, SKYCLARYS, Senza, Sunosi, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WAKIX, Xeomin, ZAVZPRET, ZEPOSIA | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error